The enigma of sepsis

Journal of Clinical Investigation

Volumn 112, Issue 4, 2003, Pages 460-467

  Riedemann, Niels C ^a   Guo, Ren Feng ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID DERIVATIVE; BACTERIUM LIPOPOLYSACCHARIDE; BRADYKININ; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; DROTRECOGIN; FLUDROCORTISONE; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; INTERLEUKIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; NITRIC OXIDE; PHOSPHODIESTERASE; PLACEBO; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; COMPLEMENT RECEPTOR; LEUKOCYTE ANTIGEN; PROTEIN C;

ANIMAL MODEL; APOPTOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOMODULATION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT FAILURE; ANIMAL; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CLINICAL TRIALS; COMPLEMENT C5A; HMGB1 PROTEIN; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PROTEIN C; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; SEPSIS;

EID: 0141608641     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200319523     Document Type: Review

References (76)

1. Angus, D.C., et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
2. Martin, G.S., Mannino, D.M., Eaton, S., and Moss, M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554.
3. Eichacker, P.Q., et al. 2002. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166:1197-1205.
4. Bone, R.C., et al. 1989. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit. Care Med. 17:389-393.
5. Goris, R.J., te Boekhorst, T.P., Nuytinck, J.K., and Gimbráere, J.S. 1985. Multiple-organ failure. Generalized autodestructive inflammation? Arch. Surg. 120:1109-1115.
6. Nuytinck, H.K., Offermans, X.J., Kubat, K., and Goris, J.A. 1988. Whole-body inflammation in trauma patients. An autopsy study. Arch. Surg. 123:1519-1524.
7. Bone, R.C., et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1644-1655.
8. Bone, R.C., Sprung, C.L., and Sibbald, W.J. 1992. Definitions for sepsis and organ failure. Crit. Care Med. 20:724-726.
9. Levy, M.M., et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31:1250-1256.
10. Thomas, L. 1972. Germs. N. Eng. J. Med. 287:553-555.
11. Bennett, I.L., et al. 1963. The effectiveness of hydrocortisone in the management of severe infection. JAMA. 183:462-465.
12. Davis, C.E., Brown, K.R., Douglas, H., Tate, W.J., 3rd, and Braude, A.I. 1969. Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J. Immunol. 102:563-572.
13. Cohen, J. 1999. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. 55:212-225.
14. Michie, H.R., et al. 1988. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 104:280-286.
15. Michie, H.R., et al. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-1486.
16. Beutler, B., Milsark, I.W., and Cerami, A.C. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:869-871.
17. Tracey, K.J., et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science. 234:470-474.
18. Tracey, K.J., et al. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:662-664.
19. Reinhart, K., and Karzai, W. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29(Suppl.):S121-S125.
20. Eskandari, M.K., et al. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
21. Newcomb, D., Bolgos, G., Green, L., and Remick, D.G. 1998. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock. 10:110-117.
22. Girardin, E., Grau, G.E., Dayer, J.M., Roux-Lombard, P., and Lambert, P.H. 1988. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319:397-400.
23. Hotchkiss, R.S., and Karl, I.E. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-150.
24. Riedemann, N.C., and Ward, P.A. 2003. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin. Biol. Ther. 3:339-350.
25. Annane, D., et al. 2002. Effect of treatment with low doses hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 288:862-871.
26. Riedemann, N.C., Guo, R.F., and Ward, P.A. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-524.
27. Fisher, C.J., Jr., et al. 1996. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334:1697-1702.
28. Bernard, G.R., et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
29. Healy, D.P. 2002. New and emerging therapies for sepsis. Ann. Pharmacother. 36:648-654.
30. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., and Ruf, W. 2002. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 296:1880-1882.
31. Siegel, J.P. 2002. Assessing the use of activated protein C in the treatment of severe sepsis. N. Engl. J. Med. 347:1030-1034.
32. Manns, B.J., Lee, H., Doig, C.J., Johnson, D., and Donaldson, C. 2002. An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347:993-1000.
33. Warren, B.L., et al. 2001. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 286:1869-1878.
34. Oberholzer, C., Oberholzer, A., Clare-Salzler, M., and Moldawer, L.L. 2001. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. 15:879-892.
35. Hotchkiss, R.S., et al. 1999. Overexpression of Bc1-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol. 162:4148-4156.
36. Hotchkiss, R.S., et al. 1999. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. U. S. A. 96:14541-14546.
37. Hotchkiss, R.S., et al. 2000. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1:496-501.
38. Coopersmith, C.M., et al. 2002. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA. 287:1716-1721.
39. Coopersmith, C.M., et al. 2002. Overexpression of Bc1-2 in the intestinal epithelium improves survival in septic mice. Crit. Care Med. 30:195-201.
40. Hotchkiss, R.S., et al. 2003. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc. Natl. Acad. Sci. U. S. A. 100:6724-6729.
41. Wang, H., et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-251.
42. Wang, H., Yang, H., Czura, C.J., Sama, A.E., and Tracey, K.J. 2001. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164:1768-1773.
43. Andersson, U., et al. 2000 High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192:565-570.
44. Fiuza, C., et al. 2002. Inflammatory promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 101:2652-2660.
45. Sappington, P.L., et al. 2002. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology. 123:790-802.
46. Ulloa, L., et al. 2002. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 99:12351-12356.
47. Calandra, T., et al. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6:164-170.
48. Bozza, M., et al. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341-346.
49. Bernhagen, J., et al. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 365:756-759.
50. Rossi, A.G., et al. 1998. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J. Clin. Invest. 101:2869-2874.
51. Rice, E.K., et al. 2003. Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney Int. 63:1265-1275.
52. Arndt, U., et al. 2002. Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection. J. Virol. 76:9298-9306.
53. Calandra, T., Bernhagen, J., Mitchell, R.A., and Bucala, R. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179:1895-1902.
54. Calandra, T., et al. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 377:68-71.
55. Lehmann, L.E., et al. 2001. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 27:1412-1415.
56. Gando, S., et al. 2001. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med. 27:1187-1193.
57. Shin, H.S., Snyderman, R., Friedman, E., Mellors, A., and Mayer, M.M. 1968. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science. 162:361-363.
58. Goldstein, I.M., and Weissmann, G. 1974. Generation of CS-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113:1583-1588.
59. Sacks, T., Moldow, C.F., Craddock, P.R., Bowers, T.K., and Jacob, H.S. 1978 Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J. Clin. Invest. 61:1161-1167.
60. Schumacher, W.A., Fantone, J.C., Kunkel, S.E., Webb, R.C., and Lucchesi, B.R. 1991. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions. 34:345-349.
61. Guo, R.F., et al. 2000. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 106:1271-1280.
62. Riedemann, N.C., et al. 2002. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16:887-888.
63. Czermak, B.J., et al. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5:788-792.
64. Huber-Lang, M.S., et al. 2002. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 16:1567-1574.
65. Riedemann, N.C., et al. 2002. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110:101-108. doi: 10.1172/JCI200215409
66. Hangen, D.H., et al. 1989. Complement levels in septic primates treated with anti-C5a antibodies. J. Surg. Res. 46:195-199.
67. Stevens, J.H., et al. 1986. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77:1812-1816.
68. Nakae, H., et al. 1994. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84:189-195.
69. Nakae, H., Endo, S., Inada, K., and Yoshida, M. 1996. Chronological changes in the complement system in sepsis. Surg. Today. 26:225-229.
70. Bengtson, A., and Heideman, M. 1988. Anaphylatoxin formation in sepsis. Arch. Surg. 123:645-649.
71. Huber-Lang, M.S., et al. 2002. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169:3223-323.
72. Guo, R.F., et al. 2003. Neutrophil C5a receptor and outcome in sepsis. FASEB J. In press.
73. Riedemann, N.C., et al. 2003. Regulation by C5a of neutrophil activation during sepsis, Immunity. In press.
74. Laudes, I.J., et al. 2002. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 160:1867-1875.
75. Rivers, E., et al. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345:1368-1377.
76. van den Berghe, G., et al. 2001. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345:1359-1367.